$CI · Cigna Group
Cigna filed its Q3 FY2026 10-Q. Total revenues rose 5.6% YoY to $73.68B, driven by pharmacy revenues up to $58.98B. Shareholders' net income fell 23% to $1.44B ($5.47 diluted EPS) from $1.87B ($6.98) a year ago, while adjusted income from operations rose 2% to $7.98 per share. Net income attributable to noncontrolling interests jumped to $256M from $105M.
- Total revenues rose 5.6% YoY to $73.68B in Q3 FY2026.
- Shareholders' net income fell 23% to $1.44B, diluted EPS $5.47 vs $6.98.
- Adjusted income from operations rose 2% to $7.98 per share.
- Net income attributable to noncontrolling interests jumped to $256M from $105M.
- Evernorth pre-tax adjusted income fell 4% to $1.83B; Cigna Healthcare rose 15% to $1.19B.
Shares are up 1.94% to $311.33, though down 0.47% from the filing-time price of $312.79, suggesting a muted reaction to mixed results.
Cigna's top-line growth masks a 23% drop in shareholders' net income as noncontrolling interests and pharmacy costs weigh on results.
Cigna's pharmacy-heavy mix (Evernorth) contrasts with peers more exposed to medical cost trends; the segment divergence mirrors broader managed-care margin pressure.
Rising noncontrolling interests and a 4% decline in Evernorth pre-tax adjusted income signal margin pressure in the core pharmacy segment.